CytomX Therapeutics Inc. Company Profile
NASDAQ: CTMXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CytomX Therapeutics at a glance
CytomX Therapeutics Inc. (NASDAQ: CTMX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in South San Francisco, CA. CytomX Therapeutics is led by Dr. Sean A. McCarthy DPHIL and employs about 69 people. The company's shares have traded publicly since 2015.
At a market capitalization of $446.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001501989, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does CytomX Therapeutics do?
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Business description based on the company's public filings.
Company information
- Legal name
- CytomX Therapeutics Inc.
- Ticker
- NASDAQ: CTMX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Sean A. McCarthy DPHIL
- Employees
- 69
- Headquarters
- 151 Oyster Point Boulevard, South San Francisco, CA, United States
- Phone
- 650 515 3185
- Website
- cytomx.com
- IPO year
- 2015
- Market cap
- $446.91M
- SEC CIK
- 0001501989
- Latest annual report
- 10-K · Mar 16, 2026
Companies similar to CytomX Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KMDAKamada Ltd. | 7.74 | -1.15% | $446.85M | vs CTMX |
| DMACDiaMedica Therapeutics Inc. | 8.25 | +2.87% | $445.15M | vs CTMX |
| AMRNAmarin Corporation plc | 10.57 | -6.13% | $444.39M | vs CTMX |
| LYELLyell Immunopharma Inc. | 13.80 | +1.62% | $441.82M | vs CTMX |
| CAPRCapricor Therapeutics Inc. | 7.59 | +0.80% | $441.30M | vs CTMX |
| STTKShattuck Labs Inc. | 4.46 | -1.98% | $454.22M | vs CTMX |
| ASMBAssembly Biosciences Inc. | 22.19 | -1.38% | $454.39M | vs CTMX |
| NGNENeurogene Inc. | 22.15 | -3.40% | $458.53M | vs CTMX |